A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors
This Phase 1a, single center, open-label, repeat dose study will evaluate the safety, efficacy, and Pharmacokinetics of ascending doses of OBP-801 in patients with advanced solid tumors.
Solid Tumor
DRUG: OBP-801
Maximum Tolerated Dose, 6 weeks
Pharmacokinetic (PK) profile; AUC, Cmax, and t1/2, 4 weeks|Objective Response (OR), 22 weeks|Durability of Objective Response (DOR), 22 weeks
This Phase 1a, single center, open-label, repeat dose study will evaluate the safety, efficacy, and Pharmacokinetics of ascending doses of OBP-801 in patients with advanced solid tumors.